期刊文献+

儿童急性淋巴细胞白血病TEL-AML1融合基因检测 被引量:4

Identification of TEL-AML1 fusion gene in childhood acute lymphoblastic leukemia
原文传递
导出
摘要 目的 检测儿童急性淋巴细胞白血病(ALL)中TEL-AML1融合基因的阳性率,探讨TEL-AML1融合基因的检测方法及其临床应用价值。方法 在形态学、免疫分型、细胞遗传学基础上,采用巢式反转录-聚合酶链反应(RT-PCR)和荧光原位杂交技术(FISH)检测31例ALL患儿骨髓单核细胞中TEL-AML1融合基因。结果 巢式RT-PCR技术和FISH技术均可以显著提高TEL-AML1融合基因的检出率,应用上述两种方法,31例患儿中检测出7例TEL-AML1阳性,占儿童初发ALL的22.6 %(7/31),在B系ALL中的阳性率为25.9 %(7/27)。结论 t(12;21)形成TEL-AML1融合基因是儿童ALL最常见的染色体易位,常规染色体核型分析极难发现,需用巢式RT-PCR或FISH等分子检测方法加以证实。 Objective To detect expression of TEL-AML1 fusion genes in pediatric cases with acute lymphoblastic leukemia(ALL) and discuss the role of reverse transcriptase polymerase chain reaction(RT-PCR) and fluorescence in situ hybridization(FISH) in detection of t(12 ;21) and the clinical significance. Methods TEL-AML1 fusion gene was identified in bone marrow mononuclear cells from 31 newly diagnosed childhood ALL patients by NRT-PCR, FISH and conventional cytogenetic analysis (CCA). Results TEL-AML1 fusion gene was found in 7 out of 31 cases, accounting for 22.6 % in pediatric ALL, and 7 out of 31 cases accounting for 25.9 % in B-ALL. Seven cases were found with t(12;21) by FISH and NRT-PCR. The incidence of the t(12;21) was 22.6 % in newly diagnosed pediatric ALLs. Conclusion It is concluded that TEL-AML1 rearrangement is a frequent molecular abnormality in childhood ALL. t(12;21) is the most common cytogenetic translocations in Chinese pediatric ALLs, but it is always difficult to identify by routine CCA. Other molecular methods, e.g. NRT-PCR and FISH are powerful in detecting such a critical genetic translocation.
出处 《白血病.淋巴瘤》 CAS 2009年第11期675-678,共4页 Journal of Leukemia & Lymphoma
关键词 白血病 淋巴细胞 急性 TEL—AML1融合基因 聚合酶链反应 原位杂交 荧光 Leukemia, lymphoblastic, acute TEL-AML1 fusion gene Polymerase chain reaction In situ hybridization, fluorescence
  • 相关文献

参考文献9

  • 1PuiCH, Relling MAV, Downing JR, et al. Acute lymphoblastic leukemia. N Engl J Med, 2004, 350: 1535-1548. 被引量:1
  • 2Romana SP, Mauchouffe M, Le-Coniat M, et al. The t(12;21) of acute lymphoblastic leukemia results in a TEL-AML1 gene fusion. Blood, 1995, 85: 3662-3670. 被引量:1
  • 3Uekun MF, Herman-Halten K, Crotty LM, et al.Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21; q23) chromosomal translocation. Blood, 1998, 92: 810. 被引量:1
  • 4Guidez F, Retrie K, Ford AM, et al. Recruitment of the nuclear receptor corepressor N -CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood, 2000, 96: 2557-2561. 被引量:1
  • 5Gunji H, Waga K, Nakamura F, et al. TEL/AML1 shows dominant negative effects over TEL as well as AML1. Biochem Biophys Res Commun, 2004, 322: 623-630. 被引量:1
  • 6Sawinska M, Ladon D. Mechanism, detection and clinical significance of the recip-- rocal translocation t (12;21)(p12;q22) in the children suffering from acute lymphoblastic leukemia. Leuk Res, 2004, 28: 35-42. 被引量:1
  • 7刘怡,李志刚,赵玮,李蓓,巩文玉,吴敏媛.儿童急性淋巴细胞白血病伴有TEL-AML1融合基因表达的免疫表型特点分析[J].中国实验血液学杂志,2006,14(4):714-716. 被引量:3
  • 8Loh ML, Goldwasser MA, Silverman LB, et al. Prospective analysis of TEL/AMLI - positive patients treated on Dana - Farber Cancer Institute Consortium Protocol 95-01. Blood, 2006, 107:4508-4513. 被引量:1
  • 9薛华,肖志坚.急性淋巴细胞白血病微小残留病检测的临床意义[J].白血病.淋巴瘤,2006,15(1):74-77. 被引量:2

二级参考文献35

  • 1叶应妩 王毓三.全国临床检验操作规程[M].南京:东南大学出版社,1991.70-73. 被引量:225
  • 2Brisco M J,Hughes E,Neoh S H,et al.Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia[J].Blood,1996,87(12):5251-5256. 被引量:1
  • 3Gokbuget N,Kneba M,Raff T,et al.Risk-adaped treatment according to minimal residual disease in adult ALL[J].Best Pract Res Clin Haematol,2002,15(4):639-652. 被引量:1
  • 4Preudhomme C,Grardel N,Huyghe P,et al.Evaluation of minimal residual disease (MRD) by competitive quantitative PCR using IGH/TCR rearrangements has prognostic value in adult acute lymphoblastic-leukemia(ALL):a single ceter study[J].Blood,2001,98:1331a. 被引量:1
  • 5Dombret H,Gabert J,Boiron J M,et al.Outcome of treatment in adults with Philadelphia chromosome positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial [J].Blood,2002,100(7):2357-2366. 被引量:1
  • 6Pui C-H,Campana D.New definition of remission in childhood acute lymphoblastic leukemia[J].Leukemia,2000,14(5):783-785. 被引量:1
  • 7Hoelzer D,Gokbuget N,Brüggemann M,et al.Clinical impact of minimal residual disease (MRD) in trial design for adult ALL(abstract)[J].Blood,2001,98:584a. 被引量:1
  • 8Gokbuget N,Raff R,Brugge-Mann M,et al.Risk/MRD adapted GMALL trials in adult ALL[J].Ann Hematol,2004,83Suppl 1:S 129-131. 被引量:1
  • 9Schrappe M.Evolution of BFM trials for childhood ALL [J].Ann Hematol,2004,83 Suppl 1:S121-123. 被引量:1
  • 10Kebriaei P,Larson R A.Progress and challenges in the therapy of adult acute lymphoblastic leukemia[J].Curr Opin Hematol,2003,10(4):284-289. 被引量:1

共引文献3

同被引文献53

  • 1孔圆,江滨,王德炳,刘开彦,黄晓军,卢锡京,孙志强,陆道培.80例青少年急性淋巴细胞白血病MICM分型与临床预后分析[J].中华血液学杂志,2004,25(7):421-424. 被引量:11
  • 2顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:473
  • 3Campana D. Status of minimal residual disease testing in childhood haematological malignancies. Br J Haematol, 2008, 143: 481-489. 被引量:1
  • 4Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood lymphoblastic leukemia. Blood, 2010, 115: 4657-4663. 被引量:1
  • 5Borowitz M J, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors:a Children's Oncology Group Study. Blood, 2008, 111: 5477-5485. 被引量:1
  • 6Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia .Hematol Oneol Clin North Am, 2009, 23: 1083-1098. 被引量:1
  • 7Coustain-Smith E, Campana D. Immunologic minimal residual disease delection in acute lymphoblastic leukemia:a comparative approach to molecular test. Best Pract Res Clin Haematol, 2010, 23: 347-358. 被引量:1
  • 8Szczepanski T, van DerveIden VH, van Dongen JJ. Flow-cytometric immunophenotyping of normal and malignant lymphocytes.Clin Chem Lab Med, 2006, 44: 775-796. 被引量:1
  • 9Vidriales MB, San-miguel JF, Orfao A, et al. Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol,2003, 16: 599-612. 被引量:1
  • 10DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia:potential usefulness in minimal residual disease detection. Cytometry B Clin Cytom, 2009, 76: 150-155. 被引量:1

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部